| Liu, Hui Liang |
NCT04790305: Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer |
|
|
| Recruiting | 4 | 1072 | RoW | Huaier Granule, Z20000109（NMPA Approval Number） | Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Carcinoma Breast, Triple-negative Breast Cancer, Invasive Ductal Carcinoma, Breast | 12/27 | 07/28 | | |
NCT04504396: Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy |
|
|
| Completed | 3 | 620 | RoW | GLP-1 receptor agonist, Placebo, PB-119 Placebo | PegBio Co., Ltd. | Type 2 Diabetes Mellitus (T2DM) | 09/22 | 05/23 | | |
NCT06545747: Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI |
|
|
| Recruiting | 3 | 304 | RoW | DCE-MRI based split-course hypo-RT, CT based split-course hypo-RT, Concurrent chemotherapy, Consolidative immunotherapy | Sun Yat-sen University | Non-small Cell Lung Cancer | 12/27 | 12/27 | | |
NCT06521255: Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Recruiting | 3 | 244 | RoW | Tafasitamab, Lenalidomide, Gemcitabine, Oxaliplatin, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | DLBCL | 09/28 | 12/29 | | |
BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 3 | 150 | RoW | Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma (DLBCL) | 07/24 | 12/25 | | |
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/25 | 08/26 | | |
NCT06734702: Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 300 | RoW | Neoadjuvant therapy, Concurrent chemoradiotherapy, Consolidative immunotherapy | Sun Yat-sen University | Neoadjuvant Therapy, Concurrent Chemoradiotherapy, Immunotherapy, Locally Advanced Non-Small Cell Lung Cancer | 11/28 | 11/28 | | |
NCT05438875: The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9 |
|
|
| Recruiting | 3 | 96 | RoW | all-trans retinoic acid, retinoic acid, Eltrombopag, TPO-RA | Peking University People's Hospital, Beijing Friendship Hospital, Beijing Tongren Hospital, Beijing Hospital, Navy General Hospital, Beijing | Purpura, Thrombocytopenic, Idiopathic | 12/24 | 03/25 | | |
GASTO-1074, NCT04980716: Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients |
|
|
| Recruiting | 3 | 524 | RoW | Multiple cardiovascular drugs related to "Golden Triangle" | Sun Yat-sen University | Non-small Cell Lung Cancer, Cardiovascular Complication | 01/26 | 07/26 | | |
GASTO 1017, NCT03006575: Study of Split-course Chemoradiotherapy For Postoperative Locoregional Recurrence Of Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 57 | RoW | split-course radiotherapy, concurrent chemotherapy | Sun Yat-sen University | Non-small Cell Lung Cancer | 06/20 | 07/21 | | |
NCT02337712: Once-daily Simultaneous Modulated Accelerated Thoracic Radiotherapy in Limited Small-cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 198 | RoW | q.d. RT, b.i.d.RT, etoposide and cisplatin | Sun Yat-sen University | Small Cell Lung Cancer | 09/20 | 12/21 | | |
NCT04610970: A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL） |
|
|
| Recruiting | 2 | 93 | RoW | TQ-B3525 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Diffuse Large B-cell Lymphoma | 03/22 | 06/22 | | |
GASTO-1066, NCT04524299: Study of Radiotherapy Combined With Albumin Bound Paclitaxel and Nedaplatin for Locally Advanced NSCLC |
|
|
| Recruiting | 2 | 160 | RoW | chest radiation(IMRT), Concurrent chemotherapy twice a week, Concurrent chemotherapy once a week | Sun Yat-sen University | Non-small Cell Lung Cancer | 05/22 | 05/24 | | |
GASTO 1052, NCT04212052: Split-course Hypofractionated Radiotherapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer |
|
|
| Completed | 2 | 104 | RoW | split-course radiotherapy, concurrent chemotherapy, consolidation immunotherapy | Sun Yat-sen University | Non-small Cell Lung Cancer | 01/23 | 12/23 | | |
NCT04787328: A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC) |
|
|
| Recruiting | 2 | 30 | RoW | HA121-28 tablets | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Medullary Thyroid Carcinoma | 03/23 | 03/25 | | |
GASTO-1053, NCT04345146: Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC |
|
|
| Completed | 2 | 100 | RoW | FSRT combined with Bevacizumab | Sun Yat-sen University | Non-small Cell Lung Cancer | 03/23 | 03/23 | | |
| Completed | 2 | 55 | RoW | Unity-based MR-Linac guided FSRT | Sun Yat-sen University | Non-small Cell Lung Cancer | 07/24 | 07/24 | | |
GASTO-1098, NCT06139419: The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC |
|
|
| Recruiting | 2 | 114 | RoW | definitive radiotherapy, induction chemo-immunotherapy, albumin-bound paclitaxel, cisplatin, tislelizumab, concurrent chemotherapy, Immunotheapy consolidation, Thymosin Alpha1, thymalfasin | Sun Yat-sen University | Non-small Cell Lung Cancer | 08/25 | 08/26 | | |
GASTO-1042, NCT03663764: Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor |
|
|
| Active, not recruiting | 2 | 57 | RoW | Thymosin a1, hypofractionated radiotherapy, concurrent chemoradiotherapy | Sun Yat-sen University | Thymoma and Thymic Carcinoma | 08/23 | 08/23 | | |
| Recruiting | 2 | 59 | RoW | Unity-based MR-Linac guided Radiotherapy | Sun Yat-sen University | Mediastinal Tumor | 10/23 | 10/23 | | |
GASTO-1091, NCT04085250: Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy |
|
|
| Active, not recruiting | 2 | 264 | RoW | Neoadjuvant therapy, Chemotherapy concurrent with radiotherapy, Radiotherapy, Nivolumab, Observation | Sun Yat-sen University | Stage III Non-small-cell Lung Cancer | 01/25 | 01/25 | | |
GASTO-10107, NCT06281886: Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 170 | RoW | Induction Immunotherapy-Toripalimab, Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin, Radiotherapy, Apatinib, Capecitabine, Chemotherapy concurrently with radiotherapy | Sun Yat-sen University | Esophageal Squamous Cell Carcinoma, Efficacy, Toxicity | 12/26 | 12/26 | | |
NCT06176235: Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia |
|
|
| Recruiting | 2 | 132 | RoW | Teriflunomide, AUBAGIO, Dexamethasone | Peking University People's Hospital, Beijing Luhe Hospital, Chinese PLA General Hospital, Navy General Hospital, Beijing, Beijing Hospital, Beijing Friendship Hospital, Peking University First Hospital, Peking University Third Hospital, China-Japan Friendship Hospital, Beijing Tsinghua Changgeng Hospital | Immune Thrombocytopenia | 12/24 | 05/25 | | |
GASTO-1071, NCT04844385: Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma |
|
|
| Active, not recruiting | 2 | 124 | RoW | Toripalimab, Paclitaxel-albumin, Nedaplatin, radiation therapy at a total dose 60 Gy, Capecitabine, radiation therapy at a total dose 50 Gy | Sun Yat-sen University | Esophageal Squamous Cell Carcinoma | 12/24 | 12/24 | | |
GASTO-1079, NCT04970693: A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression |
|
|
| Recruiting | 2 | 64 | RoW | Furmonertinib, Radiotherapy | Sun Yat-sen University | Non-small Cell Lung Cancer, Oligoprogressive | 01/24 | 05/24 | | |
GASTO-1086, NCT05468242: Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy |
|
|
| Recruiting | 2 | 116 | RoW | Neoadjuvant chemo-immunotherapy, Bevacizumab, Radiotherapy, Tislelizumab | Sun Yat-sen University | Stage III Non-small Cell Lung Cancer | 12/24 | 12/24 | | |
NCT06582940: Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis |
|
|
| Recruiting | 2 | 168 | RoW | MRI-guided adaptive SRT, Conventional SRT | Sun Yat-sen University | MRI-guided Adaptive Radiotherapy, Non-small Cell Lung Cancer, Brain Metastasis | 03/26 | 03/26 | | |
NCT06542159: Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases |
|
|
| Recruiting | 2 | 130 | RoW | Online adaptive SBRT, Conventional SBRT | Sun Yat-sen University | Adaptive Radiotherapy, Stereotactic Body Radiotherapy, Non-small Cell Lung Cancer, Lung Oligometastases, Toxicity | 04/27 | 04/28 | | |
NCT05932524: Low-dose Baricitinib Plus High-dose Dexamethasone for Patients With Newly Diagnosed Immune Thrombocytopenia |
|
|
| Recruiting | 2 | 132 | RoW | Baricitinib 2 MG, Olumiant, Dexamethasone, HD-DXM | Peking University People's Hospital, Beijing Luhe Hospital, Chinese PLA General Hospital, Navy General Hospital, Beijing, Beijing Hospital, Beijing Friendship Hospital, Peking University First Hospital, Peking University Third Hospital, China-Japan Friendship Hospital, Beijing Tsinghua Changgeng Hospital | Immune Thrombocytopenia | 06/24 | 06/25 | | |
NCT06439381: Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps |
|
|
| Recruiting | 2 | 120 | RoW | 300mg/600mg of TQH2722 injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Rhinosinusitis | 10/25 | 11/25 | | |
NCT05852847: Low-dose Baricitinib Plus Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia |
|
|
| Recruiting | 2 | 216 | RoW | Baricitinib 2 MG [Olumiant], Olumiant, Danazol | Peking University People's Hospital, Beijing Luhe Hospital, Chinese PLA General Hospital, Navy General Hospital, Beijing, Beijing Hospital, Beijing Friendship Hospital, Peking University First Hospital, Peking University Third Hospital, China-Japan Friendship Hospital, Beijing Tsinghua Changgeng Hospital | Immune Thrombocytopenia | 11/24 | 05/25 | | |
NCT06719700: Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 47 | RoW | Chemotherapy, Immunotherapy, Angio-immuno kinase inhibitor, radiotherapy, Prophylactic Cranial Irradiation, Consolidation Therapy with Toripalimab and Surufatinib | Sun Yat-sen University | Toripalimab, Surufatinib, Chemoradiotherapy, Limited-stage Small Cell Lung Cancer (LS-SCLC) | 11/28 | 11/28 | | |
| Recruiting | 2 | 35 | RoW | thoracic irradiation, Concurrent chemotherapy | Sun Yat-sen University | Loco-regionally Recurrent NSCLC After Thoracic Radiotherapy | 02/25 | 02/25 | | |
NCT06089278: A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps. |
|
|
| Recruiting | 2 | 160 | RoW | 300mg of TQH2722 injection, 600mg of TQH2722 injection, TQH2722 injection matching placebo | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Sinusitis | 05/25 | 05/25 | | |
| Active, not recruiting | 1/2 | 121 | RoW | CAR-BCMA T Cells | CARsgen Therapeutics Co., Ltd., Beijing Chao Yang Hospital, The First Affiliated Hospital of Soochow University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University General Hospital, First Affiliated Hospital of Zhejiang University, Beijing Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine, First Affiliated Hospital of Wenzhou Medical University, Xiangya Hospital of Central South University, Peking University People's Hospital, Qilu Hospital of Shandong University, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University | Multiple Myeloma | 12/24 | 12/25 | | |
NCT06083701: Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study |
|
|
| Recruiting | 1/2 | 32 | RoW | Linperlisib in combined with Chidamide | Peking Union Medical College Hospital | Peripheral T Cell Lymphoma | 09/24 | 09/25 | | |
NCT05441761: Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL |
|
|
| Recruiting | 1/2 | 60 | RoW | liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin | Peking Union Medical College Hospital, CSPC Ouyi Pharmaceutical Co., Ltd. | Treatment, Peripheral T-cell Lymphoma | 05/25 | 05/25 | | |
NCT04850560: Sequential Low-dose Decitabine With PD-1/CD28 CD19 CAR-T in Relapsed or Refractory B-cell Lymphoma |
|
|
| Recruiting | 1 | 30 | RoW | CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine | Second Affiliated Hospital, School of Medicine, Zhejiang University | Objective Response Rate | 05/22 | 05/24 | | |
NCT04537442: Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 1 | 10 | RoW | IM21 CAR-T cells | Beijing Immunochina Medical Science & Technology Co., Ltd. | Multiple Myeloma | 12/22 | 03/23 | | |
| Completed | 1 | 18 | RoW | Hypofractionated radiotherapy, Concurrent chemotherapy, Consolidation immunotherapy | Sun Yat-sen University | Locally Advanced Lung Carcinoma | 03/23 | 09/23 | | |
NCT04521686: Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations |
|
|
| Active, not recruiting | 1 | 200 | Europe, Japan, US, RoW | LY3410738, Gemcitabine, LY188011, Cisplatin, Durvalumab | Eli Lilly and Company, Loxo Oncology, Inc. | Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor | 07/23 | 05/25 | | |
NCT06310590: Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 40 | RoW | NRT6003 Injection, Yttrium-90 carbon microspheres | Chengdu New Radiomedicine Technology Co. LTD. | Unresectable Hepatocellular Carcinoma | 10/25 | 10/25 | | |
GASTO-10102, NCT06020885: Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study. |
|
|
| Recruiting | 1 | 18 | RoW | Split-course hypo-CCRT, Induction chemo-immunotherapy, Concurrent chemotherapy | Sun Yat-sen University | Esophageal Squamous Cell Carcinoma | 01/24 | 07/24 | | |
IR2022000371, NCT05453669: Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL |
|
|
| Recruiting | 1 | 12 | RoW | CD19-CAR-DNT cells | Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Ruijiamei Biotechnologies, Co., Ltd. | B-cell Non-Hodgkin's Lymphoma | 06/24 | 06/25 | | |
NCT05924750: A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1 | 26 | RoW | BL-M11D1 | Sichuan Baili Pharmaceutical Co., Ltd. | Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | 08/25 | 08/25 | | |
GASTO-10108, NCT06277388: Evaluation of Impedance Cardiography for Assessing Hemodynamic Shifts in Patients With LA-NSCLC During Treatment. |
|
|
| Recruiting | N/A | 237 | RoW | Impedance cardiography | Sun Yat-sen University | Non-small Cell Lung Cancer, Cardiac Toxicity | 06/25 | 06/25 | | |
GASTO-1067, NCT04654234: Total-body PET/CT Imaging Using the uEXPLORER in Non-small Cell Lung Cancer Patients Treated by Induction Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiotherapy |
|
|
| Completed | N/A | 15 | RoW | Total body PET/CT (uExplorer) | Sun Yat-sen University | Non-small Cell Lung Cancer | 12/23 | 12/23 | | |
NCT05278507: Comparing Arrow PICC Catheters w/ Arrowga+rd Blue Advanced Protection Performance and Safety to Unprotected PICC's |
|
|
| Recruiting | N/A | 444 | RoW | Arrowga+rd Blue Advance Protection PICC Placement, Sham Comparator PICC placement | Teleflex | Peripherally Inserted Central Catheter | 06/23 | 06/23 | | |
NCT04921774: Research on Patients With Heart Transplantation |
|
|
| Active, not recruiting | N/A | 100 | RoW | | Guangdong Provincial People's Hospital | Heart Transplant Rejection | 12/23 | 12/23 | | |
NCT06727669: Longitudinal Cohort of Thrombosis and Hemostasis Diseases |
|
|
| Recruiting | N/A | 3000 | RoW | | Peking University People's Hospital | Immune Thrombocytopenia, Thrombotic Thrombocytopenic Purpura, Hemophilia A, Acquired, Disseminated Intravascular Coagulation, Thrombophilia, Deep Vein Thrombosis, Pulmonary Embolism, Thrombotic Microangiopathies, Coagulation Factor Deficiency, Hemophilia A, Hemophilia B, Hemophilia B, Acquired, Platelet Dysfunction, Arterial Thromboembolism, Bleeding Disorder, Thrombosis | 12/29 | 12/30 | | |
| Recruiting | N/A | 80 | RoW | Tyrosine kinase inhibitor drugs., TKI treatment | Fujian Cancer Hospital | Thyroid Cancer, Tyrosine Kinase Inhibitor, Health Related Quality of Life | 01/25 | 01/26 | | |
NCT05647850: Optimization and Clinical Study of Early Prediction Model for Neonatal Acute Respiratory Distress Syndrome |
|
|
| Recruiting | N/A | 2000 | RoW | No intervention | University-Town Hospital of Chongqing Medical University | Neonatology | 12/25 | 12/25 | | |
NCT06019455: The Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy. |
|
|
| Recruiting | N/A | 500 | RoW | | Sun Yat-sen University | Lung Cancer, Esophageal Cancer | 05/27 | 05/27 | | |
| Not yet recruiting | N/A | 63 | NA | Zeus Cloud TPS V1.0, Eclipse | Sun Yat-sen University, The First Affiliated Hospital of Soochow University, The Affilicated Suzhou Science and Technology Town Hospital | Radiotherapy | 10/22 | 10/22 | | |
| He, Lin |
NCT04527393: Individualized Analgesia for Pediatric Adenotonsillectomy |
|
|
| Completed | 4 | 542 | RoW | Individualized oral morphine, Individualized group, Conventional oral morphine, Conventional group | Children's Hospital of Fudan University | Adenotonsillectomy, Analgesia | 01/24 | 01/24 | | |
| Recruiting | N/A | 10254 | RoW | | Limeng Chen | Chronic Kidney Diseases, Chronic Kidney Disease-Mineral and Bone Disorder | 12/24 | 12/24 | | |
| Recruiting | N/A | 36 | RoW | | Children's Hospital of Fudan University | Sevoflurane, Cardiac Output, Venous Return, Vascular Resistance | 03/25 | 03/25 | | |
| Tang, Shuqing |
NCT05647850: Optimization and Clinical Study of Early Prediction Model for Neonatal Acute Respiratory Distress Syndrome |
|
|
| Recruiting | N/A | 2000 | RoW | No intervention | University-Town Hospital of Chongqing Medical University | Neonatology | 12/25 | 12/25 | | |
| Zhou, Houdi |
NCT06606509: The Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM). |
|
|
| Not yet recruiting | N/A | 1000 | RoW | Continuous Glucose Monitoring System (GX-01S) | Nanjing First Hospital, Nanjing Medical University | Type1 Diabetes Mellitus | 10/26 | 06/27 | | |
